Q-omics provides the consensus-scored UCN3 profile across patient tissues and cancer cell-line models. UCN3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UCN3 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, UCN3 RNA expression shows 9,270 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where UCN3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UCN3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UCN3 survival associations across molecular data types. UCN3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UCN3 RNA expression–survival associations across cancer types. High UCN3 expression shows unfavorable associations in STAD, THCA and MESO, but favorable associations in KIRC, SCLC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UCN3 RNA expression.
This table summarizes UCN3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for UCN3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UCN3 shows lower tumor expression in COAD, KICH, LUSC, READ, THCA and LUAD. The COAD box plot shows higher UCN3 RNA expression in normal versus tumor tissue (log2 FC = −1.943, t-test p < 0.001).
This table shows molecular features associated with UCN3 in patient tissues and cancer cell lines. In patient samples, UCN3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UCN3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LUNG_SCLC.
